Izzi V, Lakkala J, Devarajan R, Savolainen ER, Koistinen P, Heljasvaara R, Pihlajaniemi T. Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia.
Leuk Res Rep 2017;
9:9-13. [PMID:
29270355 PMCID:
PMC5735295 DOI:
10.1016/j.lrr.2017.12.001]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 11/27/2017] [Accepted: 12/10/2017] [Indexed: 12/28/2022] Open
Abstract
Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes.
Extracellular matrix (ECM) expression in acute myeloid leukemia predicts relapse.
The ECM-signature is small, with only 15 genes.
High ECM-signature expression indicates an overall favorable outcome.
High ECM-signature expression predicts therapeutic stage-specific outcome.
ECM-signature expression works in RT-qPCR and microarrays.
Collapse